Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 134

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 134
---
 terminated by BCM for our default or failure to perform any of terms of the BCM Second Agreement, following a specified notice and cure period. Additionally, BCM may terminate the BCM Second Agreement if we undergo specified bankruptcy or insolvency events, following the expiration of a specified period. The NIH may terminate our license to BCM if we fail to fulfill certain obligations. Upon expiration of the term of the BCM Second Agreement in a given country, the license grant from BCM to us will be fully paid and perpetual in such country.

The BCM Second Agreement was amended in June 2019 to amend our diligence and insurance obligations. We entered into a second amendment April 2023 to further amend our diligence obligations and to terminate the obligation to pay annual maintenance fees until the first anniversary of the achievement of certain patent milestones and annually thereafter.**

<div align='center'>74</div>

Under the BCM Second Agreement, no payments were made or incurred during the three months ended March 31, 2025 and 2024 or during the years ended December 31, 2024 and 2023. No royalty fees have been incurred to date. Components of Legacy Tvardi’s Operating Results Revenue We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future, if at all. If our development efforts for TTI-101, TTI-109 or additional product candidates that we may develop in the future are successful and result in marketing approval, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from such collaboration or license agreements . Operating Expenses Our operating expenses since inception have consisted primarily of research and development expenses and general and administrative costs. Research and Development Expenses Our research and development expenses consist primarily of direct and indirect costs incurred in performing clinical and preclinical development activities. Direct costs include:

| ● | expenses incurred under agreements with consultants and third-party contract research organizations (“CROs”) that conduct research and development activities on our behalf; |

| ● | costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers; and |

| ● | costs associated with license agreements. |

Indirect costs include:

| ● | personnel costs, which includes salaries, benefits, stock-based compensation expense and travel expenses, for personnel engaged in research and development functions; |

| ● | facilities, amortization and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other